EUVIMEDEUVIMED entdecken
Crossref

Antimicrobial peptides that cross the blood–brain barrier: systematisation of data on known representatives and prospects for their use in CNS diseases

D.D. Martynov, O.V. Shamova

Biomeditsinskaya Khimiya · 2026-11 · 72 (5) · 307-326

DOI: 10.18097/pbmcr1745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomeditsinskaya Khimiya, 2026. Verfasst von D.D. Martynov und 1 weiteren Autor:innen. Die Arbeit nennt 203 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The limited permeability of the blood-brain barrier (BBB) is one of the key obstacles in the development of new drugs for treating brain disorders. Most small molecules fail to reach therapeutic concentrations within the brain parenchyma; this causes systemic toxicity, low efficacy, and the development of drug resistance in pathogens and tumor cells. Antimicrobial peptides (AMPs) represent a large, heterogeneous group of substances that exhibit a wide range of therapeutic effects and often show low toxicity toward healthy cells. Their ability to cross the BBB independently makes them promising drug candidates for the treatment of infectious, inflammatory, and oncological diseases of the brain. To date, only a small number of peptides are known to combine antimicrobial properties with their ability to cross the BBB. Despite the significant potential of this group of molecules, experimental data on the transport of AMPs across the BBB remain fragmentary and are often obtained using incomparable experimental conditions; moreover, some earlier findings require re-evaluation in light of current knowledge regarding the barrier function of the BBB. This review provides the first systematic compilation of scattered data on peptides that combine antimicrobial activity with the capacity for transcytosis across the BBB. Three key groups of peptides have been identified and analyzed: 1) proline-rich insect AMPs (apidaecin 137, oncocin, and drosocin); 2) endogenous mammalian neuropeptides (substance P, neuropeptide Y, vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating polypeptide (PACAP)); 3) cell-penetrating peptides with AMP properties (penetratin, transportan 10, pVEC). The combination of antimicrobial activity and the ability to cross BBB appears to be an achievable and reproducible characteristic for peptides of various origins, thus underlying the clear need for their discovery and development.

Zitieren

APA

Martynov, D., & Shamova, O. (2026). Antimicrobial peptides that cross the blood–brain barrier: systematisation of data on known representatives and prospects for their use in CNS diseases. Biomeditsinskaya Khimiya, 72(5), 307-326. https://doi.org/10.18097/pbmcr1745

Vancouver

Martynov D, Shamova O. Antimicrobial peptides that cross the blood–brain barrier: systematisation of data on known representatives and prospects for their use in CNS diseases. Biomeditsinskaya Khimiya. 2026;72(5):307-326. doi:10.18097/pbmcr1745

BibTeX
@article{Martynov2026,
  author = {Martynov, D.D. and Shamova, O.V.},
  title = {Antimicrobial peptides that cross the blood–brain barrier: systematisation of data on known representatives and prospects for their use in CNS diseases},
  journal = {Biomeditsinskaya Khimiya},
  year = {2026},
  volume = {72},
  number = {5},
  pages = {307--326},
  doi = {10.18097/pbmcr1745}
}
Kostenlos starten →